Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VE800
- Development stage
- Phase 2
- Lead developer
- Vedanta Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
VE800 is an investigational **oral live biotherapeutic product** from **Vedanta Biosciences** composed of a rationally defined consortium of **11 clonal human commensal bacterial strains**. It was developed as a **microbiome-based immuno-oncology therapy** intended to modulate the gut microbiome and enhance **T-cell-mediated anti-tumor immunity**, thereby potentiating the activity of **PD-1 checkpoint blockade** such as nivolumab. Publicly described clinical development focused on **advanced or metastatic cancers**, where VE800 was evaluated in combination with Bristol Myers Squibb's Opdivo in a Phase 1 study; the study's Stage 1 response rates did not meet prespecified criteria for further expansion, and the collaboration/program was subsequently paused or discontinued.
- Other names
- oral defined bacterial consortiumoral bacterial consortiumoral consortium of 11 clonal human commensal strainsconsortium of 11 clonal bacterial strainsoral live biotherapeutic
Beyond the preview
Go deeper on VE800.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VE800.